trending Market Intelligence /marketintelligence/en/news-insights/trending/gelhMydR5xHdcnvhdWl_PQ2 content esgSubNav
In This List

Gilead's hepatitis C virus therapy Vosevi wins approval in China

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


Gilead's hepatitis C virus therapy Vosevi wins approval in China

Gilead Sciences Inc.'s hepatitis C medicine Vosevi has been approved in China.

Vosevi was approved by the China National Medical Products Administration to treat chronic hepatitis C virus infection in adults with or without liver damage who have failed prior treatment with a direct-acting antiviral therapy.

Foster City, Calif.-based Gilead said the approval was backed by data from two global phase 3 studies called Polaris-1 and Polaris-4.

About 10 million people in China are infected with hepatitis C virus, Gilead said in a Dec. 20 press release.

Vosevi — a once-daily single-tablet regimen — was approved in the U.S. and EU in 2017. The therapy is a combination of sofosbuvir, velpatasvir and voxilaprevir. For the nine months ended Sept. 30, Vosevi generated $201 million in worldwide sales, down from $319 million in the same period of 2018.